Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients
ALK-positive NSCLC
DRUG: Ceritinib (LDK378)|DRUG: Nivolumab
Maximum Tolerated Dose (MTD) and/or Recommended Dose for Expansion, Study Day 42 (6 weeks)|Overall response rate (ORR), ORR (complete response (CR)+ partial response (PR)) per RECIST 1.1 as assessed by investigator, 24 Weeks
Duration of Response (DOR), 24 weeks|Disease Control Rate (DCR), 24 weeks|Time to Response (TTR), 24 weeks|Progression Free Survival (PFS), 24 weeks|Overall survival (OS), 24 weeks
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients